ArticleJournal of neuro-oncology2025
Chemotherapy in adult patients with pilocytic astrocytoma: a retrospective multicenter cohort study.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy and safety of proton radiotherapy for progressive or surgically unfavorable adult pilocytic astrocytoma: a single-center experience.Journal of neuro-oncology · 2026Article
- MEK inhibition in adult patients with pilocytic astrocytomas.NPJ precision oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePilocytic astrocytomas are circumscribed WHO grade I gliomas that predominantly affect children, although they also occur in adults. While maximal safe resection is standard treatment, until recently chemotherapy was often used in pediatrics with irresectable symptomatic tumors to delay radiotherapy. As evidence for this approach in adults is limited, we performed a multicenter retrospective cohort study on this subject.
methodsAdult patients (≥ 16 years) treated with chemotherapy between 2006 and 2020 across eight Dutch medical centers were included. Treatment response was centrally assessed using RAPNO criteria and survival outcomes were analyzed using the Kaplan-Meier method.
resultsThirty-one patients with pilocytic astrocytoma were included (median age 27 years). Most patients had received prior treatments, including radiotherapy (n = 19) and/or surgery (n = 17), with a median interval of over five years from histopathological diagnosis to the start of chemotherapy. Temozolomide was most frequently used (64.5%). The objective response rate for all types of chemotherapy was 42%, with a median progression-free survival of 20 months and a median overall survival of 49 months. Adolescents and young adults (< 40 years) showed significantly better survival outcomes.
conclusionChemotherapy offers meaningful disease control in adolescents and young adults with irresectable symptomatic pilocytic astrocytoma, after prior treatments. However, with the improved efficacy and tolerability of targeted treatments, such as BRAF/MEK inhibitors, treatment is shifting away from traditional chemotherapy and radiotherapy. Nevertheless, chemotherapy may still represent a viable treatment option in adolescent and young adults when no actionable molecular targets are identified or when targeted therapies have failed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.